The U.S. Food and Drug Administration's vaccine advisory panel on Friday voted 16-3 to recommend against providing booster shots of the Pfizer COVID-19 vaccine for individuals aged 16 and older.
The panel later voted to endorse the Pfizer booster for individuals who are aged 65 and older and for those who are at high risk.
For people aged 65 and older and those at high risk of occupational exposure, booster doses were recommended in an 18-0 vote.
It's not clear when a final FDA decision could come on booster doses, while the Centers of Disease Control and Prevention has scheduled a meeting next week to distribute boosters around the United States.
Some recommended a booster for older individuals but several experts said they want more data about whether the booster shots can contribute to myocarditis, a type of heart inflammation.
In response to the Pfizer data, FDA researchers said hours later the initial vaccine doses are sufficient and suggested that boosters may not be needed now.
An analysis by Israeli scientists published on Wednesday found that among 1.1 million people aged 60 or older who had been fully vaccinated at least five months earlier, those who received a booster were less likely to be infected or become severely ill than those who did not get the third shot.
Friday, September 17, 2021
FDA Panel Votes Against Pfizer's COVID Booster for Everyone, Recommends It for People 65 and Older
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment